Scienture Holdings, Inc. (SCNX)
$
1.61
-0.01 (-0.62%)
Key metrics
Financial statements
Free cash flow per share
-0.7460
Market cap
21.1 Million
Price to sales ratio
143.7526
Debt to equity
0.0470
Current ratio
1.0487
Income quality
0.4625
Average inventory
0
ROE
-0.2371
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
TRxADE HEALTH, Inc. is a health services IT company based in Tampa, Florida. The company specializes in providing an online web-based platform that facilitates the buying and selling of brand, generic, and non-drug products and services. This platform serves licensed pharmaceutical wholesalers and connects them with government organizations, hospitals, clinics, and independent pharmacies, thereby enhancing the accessibility and distribution of healthcare products and services. The stock is affordable at $1.61 suitable for budget-conscious investors. With a market capitalization of $21,117,404.00 the company is classified as a small-cap player. It is a key player in the Medical - Healthcare Information Services industry, contributing significantly to the overall market landscape. The stock has a low average trading volume of 122,381.00 indicating lower market activity. Additionally, it belongs to the Healthcare sector, driving innovation and growth.
Investing in Scienture Holdings, Inc. (SCNX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
Analysts predict Scienture Holdings, Inc. stock to fluctuate between $0.69 (low) and $23.77 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-07-08, Scienture Holdings, Inc.'s market cap is $21,117,404, based on 13,116,400 outstanding shares.
Scienture Holdings, Inc. pays dividends. The current dividend yield is 20.03%, with a payout of $1.50 per share.
To buy Scienture Holdings, Inc. (SCNX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SCNX. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Scienture Holdings, Inc.'s last stock split was 1:15 on 2023-06-22.
Revenue: $136,643 | EPS: $2.69 | Growth: -111.52%.
Visit https://www.trxadehealth.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $9.55 (2024-10-29) | All-time low: $0.69 (2025-04-09).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
22 days ago
TAMPA, FL, June 17, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, announced it has terminated its Equity Line of Credit (“ELOC”) facility effective as of May 22, 2025.
globenewswire.com
2 months ago
TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that Suren Ajjarapu, who has served as Chief Executive Officer (CEO) and Chairman of the Board of Directors (BOD), has stepped down from his roles with the Company, with those positions being assumed by the existing, experienced management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani.
globenewswire.com
2 months ago
TAMPA, FL, May 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that the U.S. Food and Drug Administration (FDA) has listed U.S. Patent Nos. 11890273 (the ‘273 patent) and 12156869 (the '869 patent), each with an expiration date of October 2041, in its Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) for Arbli™, (losartan potassium) Oral Suspension, 10mg/mL, approved under New Drug Application (NDA# N218772).
globenewswire.com
3 months ago
TAMPA, FL, April 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the initiation of supply chain activities by its wholly owned subsidiary Scienture, LLC to manufacture launch quantities of Arbli TM (losartan potassium) Oral Suspension, 10 mg/mL for the intended commercial launch of the product in July 2025. Scirenture, LLC's contract manufacturing partner, Saptalis Pharmaceuticals, LLC for ArbliTM has indicated to Scienture that Saptalis has the materials and capabilities to produce the batches and supply product inventory in time for the target commercial launch. In addition, Scienture, LLC has also entered into agreements with strategic partners for warehousing and distributing the product to the market through various wholesalers.
globenewswire.com
3 months ago
TAMPA, FL, April 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, announced the divestiture of its legacy Healthcare IT and Wholesale Operations subsidiaries Integra Pharma Solutions (IPS), Bonum Health, Inc., and Softell, Inc. to Tollo Health, Inc. for a total consideration of $5 million.
globenewswire.com
3 months ago
TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to provide this annual update from its Chief Executive Officer, Surendra Ajjarapu, to its stockholders.
globenewswire.com
3 months ago
TAMPA, FL, March 25, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce Michele Rath as Senior Vice President and Chief Commercial Officer (CCO) of Scienture, LLC, a wholly owned subsidiary of the Company, leading and managing Scienture, LLC's commercial operations. Under Ms. Rath's leadership, Scienture, LLC has formalized a strategic relationship with Syneos Health Commercial Services, LLC (“Syneos Health”), a premier biopharmaceutical solutions organization, by executing a Master Commercial Services Agreement with Syneos Health (the “MCSA”). Pursuant to the MCSA, Syneos Health will serve as Scienture, LLC's Contract Sales Organization (CSO). This collaboration is set to enhance Scienture, LLC's commercial capabilities and expand its market reach through Syneos Health's proven expertise in outsourced sales solutions.
globenewswire.com
4 months ago
TAMPA, FL, March 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced it has completed a draw on its Equity Line of Credit (ELOC) to support the commercial launch of Arbli™ (losartan potassium) Oral Suspension, while simultaneously announcing a temporary suspension of further ELOC draws for the next 30 trading days or until the company's stock reaches $10 per share, whichever occurs first.
globenewswire.com
4 months ago
TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc., with the brand name Arbli TM (losartan potassium) Oral Suspension, 10 mg/mL. ArbliTM is meant for the treatment of hypertension in patients greater than 6 years old, for the reduction of risk of stroke in patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy in certain patients with type 2 diabetes. Arbli TM is the first and only FDA approved ready-to-use oral liquid losartan in the U.S. market.
globenewswire.com
4 months ago
TAMPA, FL, March 06, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, Scienture, LLC (“Scienture”), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. (“Kindeva”)), for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024.
See all news